Kinled Holding

Kinled Holding is a privately held investment firm managing the multi-asset portfolio of the Anglo-Austrian Aisher family, focusing on innovative businesses across various sectors. The firm has a long track record in financing deep technological breakthroughs in advanced medical devices, robotics, precision medicine, drug discovery, and neuromodulation. Kinled holds a diversified portfolio of assets through direct and fund investments in innovative businesses across the Life Science, Financial, and Digital Technology sectors. The Aisher family has founded and invested in innovative businesses for over a century. Today, Kinled holds a portfolio of 175 investments in innovative companies, both directly and through specialized funds. In life sciences, Kinled has a laser-focus on innovation in the biomedical technology, medical devices, robotics, neuromodulation, and digital healthcare services sectors, which represents over 50% of its portfolio. In digital technologies, Kinled invests in SaaS-enabled networks and marketplaces, with a strong emphasis on digital health, where technology can democratize markets and provide consumers with greater choice of services, representing 25% of its portfolio. In fintech, Kinled invests in companies that use technology to challenge traditional established institutions by providing superior service in embedded payment platforms, insurance, real estate, lending, and banking, which represents 25% of its portfolio. Kinled is also a Founding Partner/Director/Limited Partner in ten independent funds. This includes four dedicated Life Science investment companies managed from Vienna and Zurich, with combined Assets under Management of €300M; and six Digital Technology Funds based in Vienna, Zurich, London/Copenhagen, Prague/Bratislava, and Helsinki with combined Assets under Management of €225M. Kinled has funded early-stage businesses in Austria and Switzerland that originated in universities such as Zürich, Bern, Fribourg, Geneva, Lausanne, Graz, Innsbruck, and Vienna, and has a substantial track record of developing successful international businesses from within the Innovation Park at the Swiss Federal Institute of Technology and the BioCampus of the University of Vienna, where it maintains offices and laboratories. In the United States, Kinled has funded early-stage businesses that originated in universities from Boston, Cambridge, Harvard, Houston, Massachusetts Institute of Technology, Michigan, New York, Northeastern, San Diego, San Francisco, to Stanford. In Europe, Kinled's portfolio firms were created with technology from universities such as Aix-Marseille, Amsterdam, Barcelona, Debrecen, Gdansk, Helsinki, Ljubljana, Linköping, Milan, London, Paris, Pecs, Prague, Utrecht, and Warsaw. Kinled has created a number of mechanisms to allow co-investment from sophisticated and qualified family offices who wish to support it in developing academic/scientific projects and nascent technologies. Today, all Kinled's investments are processed through independently managed incubator/accelerators that Kinled is a founder shareholder in, and two EU regulated funds that it manages, as well as a special opportunity investment company that co-invests with a number of Swiss, EU, US, and UK regulated and unregulated technology funds, that it is partners in. Kinled's success speaks for itself. It has delivered more than 50 successful exits and achieved 21 IPOs. Some of its recent achievements over the last 12 months include OrchestraBio: Achieved a 22x return on IPO value, reaching $540M in just six years; Acrivon: Delivered a 4.5x return over five years; Fusion Robotics Division (Accelus): Provided a 4x return within 36 months; Hussle: Secured a 3x return after its sale to industry leader Egym. These results highlight Kinled's ability to identify, nurture, and deliver high-growth investment opportunities, ensuring its investors are part of a success story that spans generations.